/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED
STATES/
CALGARY, June 8, 2017 /CNW/ - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) today announced that it
will undertake an overnight marketed offering of units, comprised
of common shares and common share purchase warrants. The offering
is being led by Bloom Burton Securities Inc. on a best efforts
agency basis. The offering is to be effected in each of the
Canadian provinces, other than Quebec, by way of a prospectus supplement to
Resverlogix's base shelf prospectus dated October 1, 2015. Prior to the completion of the
offering, Resverlogix has 105,701,543 common shares issued and
outstanding. The number of units to be distributed, the price of
each unit and the exercise price and term of each whole common
share purchase warrant will be determined in context of the
market.
This transaction is subject to satisfaction of customary closing
conditions, including the receipt of all necessary regulatory and
stock exchange approvals.
The securities described herein have not been, and will not be,
registered under the United States Securities Act of 1933, as
amended (the "U.S. Securities Act"), or any state securities laws,
and accordingly, may not be offered or sold to, or for the account
or benefit of, persons in the United
States or to U.S. Persons (as such term is defined in
Regulation S under the U.S. Securities Act), except in compliance
with the registration requirements of the U.S. Securities Act and
applicable state securities requirements or pursuant to exemptions
therefrom. This press release does not constitute an offer to sell
or a solicitation of an offer to buy any of the Company's
securities to, or for the account or benefit of, persons in
the United States or U.S.
Persons.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a
first-in-class, small molecule that is a selective BET (bromodomain
and extra-terminal) inhibitor. BET bromodomain inhibition is an
epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the
second bromodomain (BD2) within the BET protein called BRD4. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease (CVD), diabetes
mellitus (DM), chronic kidney disease, dialysis, Alzheimer's
disease, Fabry disease, other orphan diseases, and peripheral
artery disease, while maintaining a well described safety profile.
Apabetalone is the only selective BET bromodomain inhibitor in
human clinical trials. Apabetalone is currently being studied in a
Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM
and low high-density lipoprotein (HDL), and is expected to be
initiated in a Phase 2a kidney dialysis trial designed to evaluate
biomarker changes and safety parameters in up to 30 patients with
end-stage renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter:
@Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on
our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking
information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
In particular, this news release includes forward looking
information relating to the completion of the offering and the
potential role of apabetalone in the treatment of CVD, DM, chronic
kidney disease, end-stage renal disease treated with hemodialysis,
Alzheimer's disease, Fabry disease, and orphan diseases. Our actual
results, events or developments could be materially different from
those expressed or implied by these forward-looking statements. We
can give no assurance that any of the events or expectations will
occur or be realized. By their nature, forward-looking statements
are subject to numerous assumptions and risk factors including
those discussed in our Annual Information Form and most recent
MD&A which are incorporated herein by reference and are
available through SEDAR at www.sedar.com. The forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement and are made as of the date hereof.
The Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Resverlogix Corp.